Cipla Partners with Qilu Pharmaceutical to Launch Keytruda Biosimilar in US
Cipla's wholly owned subsidiary, Invagen Pharmaceuticals, has partnered with China's Qilu Pharmaceutical to license and supply QL2107, a biosimilar of Merck's cancer drug Keytruda, in the United States. Under the agreement, Qilu will handle development, regulatory approvals, manufacturing, and supply, while Cipla will manage commercialization in the US. The collaboration aims to improve patient access to affordable cancer therapies and expand Cipla's oncology biosimilars portfolio ahead of Keytruda's 2028 patent expiry.
First-hand measurement across 5 sources
We measured how 5 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (62/100). Lens Score 44/100.
Outlets measured: economictimes, businessstandard, businessstandard, english, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 3 Sept, 06:46 pm. Other outlets followed.